Kymera Therapeutics (KYMR) : atopic dermatitis potential matches Sanofi/Regeneron's blockbuster Dupixent in early biomarker response

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine.

The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.

Sector: Healthcare

Industry: Biotechnology

Full Time Employees: 208

Founded by Bruce Lee Booth and Nello Mainolfi in September 2015 

Headquartered in Watertown, Massachusetts

https://www.kymeratx.com

IPO: Aug 21, 20

 

 

 

 

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. 

Telix Pharmaceuticals (TLX) began trading on the Nasdaq on Thur 14 Nov 24

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. 

• Sector: Healthcare
• Industry: Biotechnology
• Founded by Andreas Kluge and Christian P. Behrenbruch in 2015 
• Headquartered in Melbourne, Australia
• https://telixpharma.com

Septerna (SEPN) began trading on the Nasdaq on Fri 25 Oct 24

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. 

Septerna was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 68
• Incorporated in 2019 
• Headquartered in South San Francisco, California
• https://septerna.com

Septerna opened at $23.50 after pricing 16.0 mln share IPO at $18/share, above the $15-17 expected range

Septerna, a clinical-stage pharmaceutical company with an initial focus on rare endocrine diseases, draws strong interest for its IPO

• After pricing its upsized 16.0 mln share IPO at $18, above the $15-$17 expected price range, Septerna (SEPN) opened for trading at $23.50, good for a 31% opening gain. 
• The company has developed a proprietary "Native Complex Platform" that it believes will usher in a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery. GPCRs are a family of cell membrane receptors that regulate physiological processes in nearly every organ system in the human body.
• Its lead product candidate is SEP-876, which is currently in Phase 1 studies and being evaluated for the treatment of Hypoparathyroidism -- a rare endocrine disease characterized by insufficient levels of parathyroid hormone that affects approximately 70,000 patients in the United States. The company expects to report data on the trial in mid-2025.
• Including the proceeds from this offering, SEPN has approximately $400.0 mln in cash and cash equivalents. SEPN believes that it will have enough capital to fund its operations and clinical trials into 2H27.